Group items tagged pharma - medindia

Chindex to be acquired by TPG and Fosun Pharma - 0 views

processandproduction.pharmaceutical-business-review.com/...nd-fosun-pharma-180214-4179302

health medical news pharma

shared by Alex Parker on 19 Feb 14 - No Cached

Alex Parker on 19 Feb 14

Chindex International has entered into a definitive merger agreement with a buyer consortium of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group)

<div class="cArrow"> </div><div class="cContentInner">Chindex International has entered into a definitive merger agreement with a buyer consortium of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group)</div>

...

Cancel

Malaysia Bans Obedient Wives' 'Islamic Sex Guide' | MedIndia - 0 views

www.medindia.net/...-Islamic-Sex-Guide-92917-1.htm

Sex guide Malaysia polygamy Obedient Wives' Club daily health news for the day dental pharma medical breakthroughs topic

shared by med india on 05 Nov 11 - No Cached

med india on 05 Nov 11

Sex guide, Malaysia, polygamy, Obedient Wives' Club, daily health news, news for the day, dental news, pharma news, medical breakthroughs, daily news, health topic news

<div class="cArrow"> </div><div class="cContentInner">Sex guide, Malaysia, polygamy, Obedient Wives' Club, daily health news, news for the day, dental news, pharma news, medical breakthroughs, daily news, health topic news</div>

...

Cancel

Dainippon's Latuda gets approval in Canada to treat bipolar depression - 1 views

regulatoryaffairs.pharmaceutical-business-review.com/...olar-depression-040414-4209058

health news medical pharma

shared by Alex Parker on 04 Apr 14 - No Cached

Alex Parker on 04 Apr 14

Dainippon Sumitomo Pharma (DSP) has received approval from Health Canada for use of Latuda (lurasidone HCl) as monotherapy or as adjunctive therapy with lithium or valproate to treat depressive episodes associated with bipolar I disorder.

<div class="cArrow"> </div><div class="cContentInner">Dainippon Sumitomo Pharma (DSP) has received approval from Health Canada for use of Latuda (lurasidone HCl) as monotherapy or as adjunctive therapy with lithium or valproate to treat depressive episodes associated with bipolar I disorder.</div>

...

Cancel

Malaria- A Review of Recent Guidelines in the Indian Context | MedIndia - 0 views

med india on 09 Dec 11

Microscopy of blood smears remains the gold standard for confirmation of diagnosis of malaria.

<div class="cArrow"> </div><div class="cContentInner">Microscopy of blood smears remains the gold standard for confirmation of diagnosis of malaria. </div>

...

Cancel

Brain-damaged Patients in Vegetative State Respond to EEG Scan: Study | MedIndia - 0 views

www.medindia.net/...-to-EEG-Scan-Study-93170-1.htm

EEG brain damaged coma vegetative state daily health news for the day dental pharma medical breakthroughs topic

shared by med india on 10 Nov 11 - No Cached

med india on 10 Nov 11

Electro-encephalography (EEG) enlightened doctors that several patients diagnosed as being in a permanently vegetative state were in fact aware.

<div class="cArrow"> </div><div class="cContentInner">Electro-encephalography (EEG) enlightened doctors that several patients diagnosed as being in a permanently vegetative state were in fact aware.</div>

...

Cancel

Epic Sciences partners with LabCorp for circulating tumor cell technology - 0 views

itsoftware.pharmaceutical-business-review.com/...cell-technology-300114-4168451

health medical news pharma

shared by Alex Parker on 31 Jan 14 - No Cached

Alex Parker on 31 Jan 14

Epic Sciences has announced an agreement with Laboratory Corporation of America Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.

<div class="cArrow"> </div><div class="cContentInner">Epic Sciences has announced an agreement with Laboratory Corporation of America Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.</div>

...

Cancel

Immuneering expands relationship with Bristol-Myers Squibb - 0 views

itsoftware.pharmaceutical-business-review.com/...ol-myers-squibb-300114-4168880

health medical news pharma

shared by Alex Parker on 31 Jan 14 - No Cached

Alex Parker on 31 Jan 14

Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.

<div class="cArrow"> </div><div class="cContentInner">Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.</div>

...

Cancel

BioLight announces start of clinical study with DiagnosTear dry eye syndrome diagnostic... - 0 views

laboratoryinstrumentation.pharmaceutical-business-review.com/...iagnostic-assay-110214-4175302

news medical health pharma

shared by Alex Parker on 11 Feb 14 - No Cached

Alex Parker on 11 Feb 14

BioLight Life Sciences Investments announced that DiagnosTear has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.

<div class="cArrow"> </div><div class="cContentInner">BioLight Life Sciences Investments announced that DiagnosTear has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.</div>

...

Cancel

Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...roved-in-canada-140214-4177946

health medical news pharma

shared by Alex Parker on 17 Feb 14 - No Cached

Alex Parker on 17 Feb 14

Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.

<div class="cArrow"> </div><div class="cContentInner">Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.</div>

...

Cancel

Aegis awarded its first patent for oral delivery of nucleotide-based drugs - 0 views

processandproduction.pharmaceutical-business-review.com/...ide-based-drugs-060214-4172952

health medical news pharma

shared by Alex Parker on 06 Feb 14 - No Cached

Alex Parker on 06 Feb 14

Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology

<div class="cArrow"> </div><div class="cContentInner">Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology</div>

...

Cancel

DARPA's vaccine manufacturing challenge - 0 views

www.pharmaceutical-technology.com/...anufacturing-challenge-4171658

health medical news pharma

shared by Alex Parker on 13 Feb 14 - No Cached

Alex Parker on 13 Feb 14

The prospect of global pandemic is worrying for public health authorities, with the sufficient supply of vaccines a particular concern. In the US, DARPA's Blue Angel project has been working on alternative plant-based vaccine production methods, with impressive results.

<div class="cArrow"> </div><div class="cContentInner">The prospect of global pandemic is worrying for public health authorities, with the sufficient supply of vaccines a particular concern. In the US, DARPA's Blue Angel project has been working on alternative plant-based vaccine production methods, with impressive results.</div>

...

Cancel

Agenus acquires Swiss biopharmaceutical firm 4-Antibody - 0 views

drugdiscovery.pharmaceutical-business-review.com/...firm-4-antibody-140214-4177763

health medical news pharma

shared by Alex Parker on 14 Feb 14 - No Cached

Alex Parker on 14 Feb 14

US-based developer of new immunotherapeutics, including a portfolio of checkpoint modulators, anti-cancer vaccines and adjuvants, Agenus has completed the acquisition of Switzerland-based biopharmaceutical firm 4-Antibody.

<div class="cArrow"> </div><div class="cContentInner">US-based developer of new immunotherapeutics, including a portfolio of checkpoint modulators, anti-cancer vaccines and adjuvants, Agenus has completed the acquisition of Switzerland-based biopharmaceutical firm 4-Antibody.</div>

...

Cancel

CHA announces new program to accelerate innovation in life sciences and health care - 0 views

itsoftware.pharmaceutical-business-review.com/...and-health-care-250214-4183893

health news pharma

shared by Alex Parker on 25 Feb 14 - No Cached

Alex Parker on 25 Feb 14

Published 25 February 2014 Cambridge Healthtech Associates (CHA) has announced a new program to accelerate innovation in life sciences and health care. Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process.

<div class="cArrow"> </div><div class="cContentInner">Published 25 February 2014 Cambridge Healthtech Associates (CHA) has announced a new program to accelerate innovation in life sciences and health care. Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process.</div>

...

Cancel

Bristol-Myers Squibb gets FDA breakthrough designation for daclatasvir-based regimen - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...r-based-regimen-250214-4183423

health medical news pharma breakthroughs

shared by Alex Parker on 25 Feb 14 - No Cached

Alex Parker on 25 Feb 14

PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).</div>

...

Cancel

Novartis announces acquisition of CoStim Pharmaceuticals - 0 views

processandproduction.pharmaceutical-business-review.com/...pharmaceuticals-180214-4179543

health news pharma

shared by Alex Parker on 19 Feb 14 - No Cached

Alex Parker on 19 Feb 14

Novartis has acquired CoStim Pharmaceuticals, an immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

<div class="cArrow"> </div><div class="cContentInner">Novartis has acquired CoStim Pharmaceuticals, an immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.</div>

...

Cancel

Pluristem files orphan drug application to US FDA for preeclampsia - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...or-preeclampsia-210214-4182176

health pharma news

shared by Alex Parker on 24 Feb 14 - No Cached

Alex Parker on 24 Feb 14

PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.</div>

...

Cancel

Vertex gets FDA approval for Kalydeco sNDA - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...r-kalydeco-snda-240214-4182411

health medical news pharma day

shared by Alex Parker on 24 Feb 14 - No Cached

Alex Parker on 24 Feb 14

PBR Staff Writer Published 24 February 2014 US-based biotechnology firm Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) of its Kalydeco (ivacaftor) for the treatment of people with cystic fibrosis (CF).

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 24 February 2014 US-based biotechnology firm Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) of its Kalydeco (ivacaftor) for the treatment of people with cystic fibrosis (CF).</div>

...

Cancel

Novavax announces extension of contract with HHS-BARDA - 0 views

drugdiscovery.pharmaceutical-business-review.com/...-with-hhs-barda-280214-4186785

health news medical pharma

shared by Alex Parker on 04 Mar 14 - No Cached

Alex Parker on 04 Mar 14

Novavax has announced the execution of a contract modification to extend the base period of performance of its current contract with the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority

<div class="cArrow"> </div><div class="cContentInner">Novavax has announced the execution of a contract modification to extend the base period of performance of its current contract with the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority</div>

...

Cancel

GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment - 0 views

manufacturing.pharmaceutical-business-review.com/...aemia-treatment-030314-4188314

health news medical pharma

shared by Alex Parker on 04 Mar 14 - No Cached

Alex Parker on 04 Mar 14

GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment

<div class="cArrow"> </div><div class="cContentInner">GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment</div>

...

Cancel

Perrigo buys OTC products from Aspen Global for $51m - 1 views

otc.pharmaceutical-business-review.com/...-global-for-51m-040314-4189257

health news pharma

shared by Alex Parker on 05 Mar 14 - No Cached

Alex Parker on 05 Mar 14

Ireland-based Perrigo Company has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51m.

<div class="cArrow"> </div><div class="cContentInner">Ireland-based Perrigo Company has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51m.</div>

...

Cancel

Group items tagged

Chindex to be acquired by TPG and Fosun Pharma - 0 views

Malaysia Bans Obedient Wives' 'Islamic Sex Guide' | MedIndia - 0 views

Dainippon's Latuda gets approval in Canada to treat bipolar depression - 1 views

Malaria- A Review of Recent Guidelines in the Indian Context | MedIndia - 0 views

Brain-damaged Patients in Vegetative State Respond to EEG Scan: Study | MedIndia - 0 views

Epic Sciences partners with LabCorp for circulating tumor cell technology - 0 views

Immuneering expands relationship with Bristol-Myers Squibb - 0 views

BioLight announces start of clinical study with DiagnosTear dry eye syndrome diagnostic... - 0 views

Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views

Aegis awarded its first patent for oral delivery of nucleotide-based drugs - 0 views

DARPA's vaccine manufacturing challenge - 0 views

Agenus acquires Swiss biopharmaceutical firm 4-Antibody - 0 views

CHA announces new program to accelerate innovation in life sciences and health care - 0 views

Bristol-Myers Squibb gets FDA breakthrough designation for daclatasvir-based regimen - 0 views

Novartis announces acquisition of CoStim Pharmaceuticals - 0 views

Pluristem files orphan drug application to US FDA for preeclampsia - 0 views

Vertex gets FDA approval for Kalydeco sNDA - 0 views

Novavax announces extension of contract with HHS-BARDA - 0 views

GSK submits sNDA for Promacta to FDA for severe aplastic anaemia treatment - 0 views

Perrigo buys OTC products from Aspen Global for $51m - 1 views

Related searches